(FOX19) - The Perrigo Company (NYSE: PRGO; TASE) announced today that it has initiated a voluntary, nationwide product recall to the retail level of 18 batches of its acetaminophen infant suspension liquid.
The recall is for the 160 mg/5 mL, sold in 2 oz. and 4 oz. bottles with syringes in a box under the store brand products listed at www.fda.gov/safety/recalls.
The recall is being initiated because of the remote potential that a small number of packages might contain an oral dosing syringe without dose markings.
The correct syringe should have a white or yellow plunger with specific dose markings for 1.25 mL, 2.5 mL, 3.75 mL, and 5 mL.
If the product's syringe has these dose markings, consumers can continue to use the product while following labeled use instructions.
Using an oral syringe without dose markings can result in inaccurate dosing, especially in infants who could mistakenly get too high a dose.
Commenting on this market action, Perrigo's Chairman, President and CEO Joseph C. Papa stated, "There are no issues or concerns with respect to the safety or efficacy of the product, only the potential that the oral dosing device in a relatively small number of packages could be unmarked. Out of an abundance of caution, we are taking this measure to maintain the highest possible product quality standards for our retail customers and consumers. While we cannot be certain that any of these unmarked dosing devices were released into our customers' supply chains, taking this action is the right thing to do."
Perrigo has not received any reports or complaints related to this defect nor have they found any product with missing dose markings on re-examination of product on hand.
This OTC product is indicated for the relief of fever and minor aches and pains and can be used in infants, children and adults. These recalled products are sold by distributors nationwide and distributed through retail stores.
Distributors/retailers that have the acetaminophen infant suspension liquid that is being recalled should stop distribution and return product.
If the oral dosing device contained in the package has dose markings, no action is required, and the consumer can continue to use the product consistent with the label instructions.
If the package contains an oral dosing device that does not have dose markings, the consumer should not use the product and should call Perrigo's Consumer Affairs Department, toll free, 1-800-719-9260.
Consumers should contact their physician or healthcare provider if they have any questions, or if they or their children experience any problem that could possibly be related to this drug product.
Adverse events that may be related to the use of this product may be reported to FDA's MedWatch Adverse Event Reporting Program online at www.fda.gov/MedWatch/report.htm